You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
Limited impact of omega-3 fatty acids in patients with multiple cardiovascular risk factors
  1. Philip Calder
  1. Faculty of Medicine, University of Southampton, Southampton, UK
  1. Correspondence to : Dr Philip Calder, Faculty of Medicine, University of Southampton, IDS Building, MP887 Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK; pcc{at}soton.ac.uk

https://doi.org/10.1136/eb-2013-101440

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Roncaglioni MC, Tombesi M, et al. Risk and Prevention Study Collaborative Group. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 2013;368:1800–8OpenUrlCrossRefPubMedWeb of Science

    Context

    Ecological, case–control and prospective studies consistently demonstrate reduced cardiovascular morbidity and mortality associated with higher intake of fish and their constituent omega-3 fatty acids and with higher omega-3 fatty acid status.1 This effect has been ascribed to improvement of the cardiovascular risk profile resulting in disease prevention.1 Trials in patients following myocardial infarction (MI) or with heart failure demonstrated significantly lowered mortality with pharmaceutical grade omega-3 ethyl esters at a dose of approximately 850 mg/day,2 ,3 suggesting a therapeutic effect in at-risk patients. This may be due to a reduction in cardiac arrhythmias, although this effect has not been demonstrated unequivocally, …

    View Full Text

    Footnotes

    • Competing interests PC serves on the Scientific Advisory Boards of Danone Research Center in Specialised Nutrition, Pronova Biopharma, Aker Biomarine and Smartfish. He also acts as a consultant to Mead Johnson Nutritionals, Abbott Laboratories, Vifor Pharma, Amarin and Qualitas Health. He has also received speaking fees from Fresenius-Kabi, BBraun Melsungen, DSM, Nestle, Unilever and Abbott Laboratories and currently receives research funding from Vifor Pharma.